TMX group

Ticker Symbol: CUR

QUEBEC CITY, Nov. 3 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a leading
developer and provider of high-value cell-based assays and molecular
diagnostics for the early detection of cancer, today announced that effective
immediately it will stop funding its under performing subsidiary, SAMBA
Technologies SAS, of Meylan, France.
The decision to withdraw support for the subsidiary was taken as part of
a comprehensive review of DiagnoCure's business strategy. "We are currently
reviewing all our operations in order to maximise shareholder value and
strengthen our position going forward as a leader in molecular diagnostics for
the early detection of cancer; Samba is outside of our molecular diagnostics
focus," said John Schafer, President and Chief Executive Officer of
DiagnoCure.
"Because Samba's technology is not central to our current and future
direction, and the subsidiary has been unable to make a positive contribution
to DiagnoCure's bottom line, it is no longer prudent to sustain its
operations," Thom Skinner, Chief Financial Officer of DiagnoCure stated
Friday.
DiagnoCure's association with Samba started in 2002 with a software
development project to automate the microscopy reading of ImmunoCyt(TM) /
uCyt+(TM), DiagnoCure's bladder cancer test. This decision will not affect
ImmunoCyt(TM) / uCyt+(TM).
The action to withdraw support of the Samba operations will result in the
subsidiary being treated in DiagnoCure's year-end accounts, as at October 31,
2006, as "discontinued operations". The company expects to take a one time,
non-cash charge of approximately $750,000, representing the write-off of its
initial investment and accumulated losses in this subsidiary, and incur
approximately $125,000 of expense associated with the action. DiagnoCure
expects that this move will reduce future losses by approximately $200,000 per
quarter.

About DiagnoCure

DiagnoCure specialises in the development, production and
commercialisation of diagnostic tests for the early detection of cancers.
DiagnoCure's first product, ImmunoCyt(TM) / uCyt+(TM), is an important tool
for the diagnosis and monitoring of bladder cancer. In 2003, the Company
granted an exclusive worldwide license for the use of the PCA3 technology in
prostate cancer diagnosis to Gen-Probe. Tests based on the PCA3 gene, believed
to be the most accurate indicator of prostate cancer, will be introduced in
Europe this fall and are currently available in Analyte Specific Reagent
format (ASR) in the United States. DiagnoCure is now exploring additional
applications for the early detection of lung and kidney cancer. DiagnoCure is
headquartered in Quebec City, Canada. For more information, go to
www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypothesis and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward- looking statements. The forward-looking statements regarding
future revenues or the reduction of future losses are based on management
expectations. In addition, the reader is referred to the applicable general
risks and uncertainties described in DiagnoCure's most recent Annual
Information Form under heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.
%SEDAR: 00003671EF